Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daniel O'Day
Pharma
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Despite the $2.4 billion impairment charge, Gilead believes Trodelvy has a future in NSCLC.
Angus Liu
Apr 26, 2024 11:21am
Gilead CEO Daniel O'Day collects 5% pay raise to $22.6M
Mar 19, 2024 1:13pm
PhRMA taps Gilead CEO Dan O'Day as its new board chair
Feb 21, 2024 2:51pm
Struggling Biogen paid its 2 CEOs more than $57M last year
May 1, 2023 10:47am
Gilead handed its CEO Daniel O'Day a healthy pay bump in 2022
Mar 24, 2023 9:55am
Gilead sees 33% of revenue coming from oncology drugs in 2030
Apr 18, 2022 3:15pm